Current Perspectives on Stability of Protein Drug Products during Formulation, Fill and Finish Operations

Biotechnology Progress - Tập 24 Số 3 - Trang 504-514 - 2008
Nitin Rathore1, Rahul S. Rajan2
1Drug Product & Device Development, Amgen Inc. Thousand Oaks, California 91320
2Process and Product Development, Amgen Inc., Thousand Oaks, California 91320

Tóm tắt

AbstractCommercialization of protein‐based therapeutics is a challenging task in part due to the difficulties in maintaining protein solutions safe and efficacious throughout the drug product development process, storage, transportation and patient administration. Bulk drug substance goes through a series of formulation, fill and finish operations to provide the final dosage form in the desired formulation and container or delivery device. Different process parameters during each of these operations can affect the purity, activity and efficacy of the final product. Common protein degradation pathways and the various physical and chemical factors that can induce such reactions have been extensively studied for years. This review presents an overview of the various formulation‐fill‐finish operations with a focus on processing steps and conditions that can impact product quality. Various manufacturing operations including bulk freeze‐thaw, formulation, filtration, filling, lyophilization, inspection, labeling, packaging, storage, transport and delivery have been reviewed. The article highlights our present day understanding of protein instability issues during biopharmaceutical manufacturing and provides guidance on process considerations that can help alleviate these concerns.

Từ khóa


Tài liệu tham khảo

10.1016/S1387-2656(02)08004-3

10.1016/S0378-5173(99)00152-0

10.1002/jps.20727

10.1016/j.semcdb.2003.12.008

10.1021/ar050069h

10.1002/jps.20515

10.1038/nbt1096-1283

10.1073/pnas.181479798

10.1208/aapsj080367

Wyatt P. J., 1991, Combineddifferential light scattering with various liquid chromatography separation techniques, Biochem. Soc. Trans., 19, 10.1042/bst0190485

10.1002/jps.20319

10.1002/jps.20966

10.1016/S0378-4347(00)00548-X

10.1007/s11095-007-9241-4

10.1002/elps.200500567

10.1016/j.chroma.2005.10.053

Webb S. D., 2002, Freezing biopharmaceutical using common techniques and the magnitude of bulk scale freeze‐concentration, BioPharm, 15, 22

Lashmar U. T., 2007, Bulk freeze‐thaw of macromolecules‐Effect of cryoconcentration on their formulation and stability, BioProcess Int., 5, 44

Glaser V., 2005, Addressing stability of biological drugs, Gen. Eng. Biotechnol. News, 25

10.1002/jps.10184

10.3109/10409239009090612

10.1529/biophysj.104.051722

10.1073/pnas.88.17.7715

10.1002/bit.10612

10.1016/S0006-3495(96)79640-6

10.1023/A:1016270103863

10.1023/A:1015888704365

10.1021/js960080y

10.1016/S0001-8686(00)00032-4

10.1016/S0378-5173(99)00226-4

Singh S. K., 2007, Storageconsiderations as part of the formulation development program for biologics, Am. Pharm. Rev., 10, 26

Scott C.Formulation development: Making the medicine.BioProcess Int.2006 March 42–56.

10.1002/jps.20145

Chang D.;Chang R.Review of current issues in pharmaceutical excipients.Pharm. Technol.2007.

10.1016/0141-0229(81)90068-5

10.1016/S0141-0229(01)00340-4

10.1016/j.ejpb.2004.12.004

10.1021/bp0701261

Bee J., 2007, Abstracts of Papers, 234th National Meeting of theAmerican Chemical Society, Boston, MA, 2007

10.1002/jps.21029

Stockdale D.Overview of aseptic fill/finish manufacturing.Am. Pharm. Rev.2004.

DeGrazio F. L., 2006, Focuson fill and finish: Parenteral packaging concerns for biotech drugs‐Compatibility is key,, BioProcess Int., 4, 12

10.1016/S0168-1656(00)00242-X

Gabrielson J., 2007, Abstracts of Papers, 234th National Meeting of theAmerican Chemical Society, Boston, MA, 2007

10.1002/(SICI)1097-0290(19970620)54:6<503::AID-BIT1>3.0.CO;2-N

10.1016/j.biotechadv.2007.01.006

10.1007/978-1-4615-0549-5

10.1002/jps.20842

MacKenzie A. P., 1976, Thephysico‐chemical basis for the freeze‐drying process, Dev. Biol. Stand., 36, 51

10.1007/978-1-4615-0557-0_5

10.1016/S0169-409X(00)00144-7

10.1021/js980126i

10.1002/jps.21017

10.1081/PDT-120027421

10.1023/A:1012180707283

Carpenter J. F., 2004, Freezing‐ and drying‐induced perturbations of protein structure and mechanisms of protein protection by stabilizing additives, Drugs Pharm. Sci., 137, 147

10.1021/bk-1994-0567.ch008

10.1016/S0939-6411(98)00005-8

10.1002/jps.20630

10.1002/jps.20416

10.1208/pt040214

10.1023/B:PHAM.0000016234.73023.75

10.1021/bk-1997-0675.ch006

10.1016/S0939-6411(98)00007-1

10.1208/pt050458

10.1208/pt070239

Thurow H., 2004, Stabilization of dissolved proteins against denaturation at hydrophobic interfaces, Diabetologia, 27, 212, 10.1007/BF00273809

10.1002/jps.20321

10.1002/jps.2600700507

Allain L., 2007, Impact of package leachables on the stability of pharmaceutical products, Am. Pharm. Rev., 10, 38

Swift R.;Nashed‐Samuel Y.;Liu W.;Narhi L.;Davice J.Tungsten prefilled syringes and protein aggregation ACS National Conference 2007.

Harrison B.;Rios M.Big Shot: Developments in Pre‐filled syringes Pharm. Tech.2007.

10.1002/jps.20365

10.1002/jps.20815

Davies M. J., 1997, Radical‐Mediated Protein Oxidation, 10.1093/oso/9780198500971.001.0001

10.1016/0891-5849(94)00158-G

10.1016/S1011-1344(01)00208-1

10.3109/02713688408997195

10.1111/j.1751-1097.1975.tb06754.x

10.1021/js970143s

10.1177/0040517506061962

10.1016/0076-6879(84)07026-9

Thông tin
Thông tin xuất bản

Biotechnology Progress

Tập 24 Số 3

504-514

Thông tin tác giả